- Home
- TRX vs HOWL Comparison
TRX vs HOWL Comparison
Compare TRX & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRX
- HOWL
- Stock Information
- Founded
- TRX 1990
- HOWL 2017
- Country
- TRX Canada
- HOWL United States
- Employees
- TRX N/A
- HOWL N/A
- Industry
- TRX
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- TRX
- HOWL Health Care
- Exchange
- TRX Nasdaq
- HOWL Nasdaq
- Market Cap
- TRX 94.5M
- HOWL 47.1M
- IPO Year
- TRX N/A
- HOWL 2021
- Fundamental
- Price
- TRX $0.33
- HOWL $1.32
- Analyst Decision
- TRX Strong Buy
- HOWL Strong Buy
- Analyst Count
- TRX 1
- HOWL 3
- Target Price
- TRX $1.50
- HOWL $8.33
- AVG Volume (30 Days)
- TRX 447.8K
- HOWL 544.9K
- Earning Date
- TRX 07-22-2025
- HOWL 08-07-2025
- Dividend Yield
- TRX N/A
- HOWL N/A
- EPS Growth
- TRX N/A
- HOWL N/A
- EPS
- TRX 0.00
- HOWL N/A
- Revenue
- TRX $47,731,000.00
- HOWL $1,143,000.00
- Revenue This Year
- TRX $51.45
- HOWL N/A
- Revenue Next Year
- TRX $26.19
- HOWL N/A
- P/E Ratio
- TRX $319.30
- HOWL N/A
- Revenue Growth
- TRX 26.50
- HOWL N/A
- 52 Week Low
- TRX $0.27
- HOWL $0.60
- 52 Week High
- TRX $0.45
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- TRX 56.07
- HOWL 62.41
- Support Level
- TRX $0.33
- HOWL $1.03
- Resistance Level
- TRX $0.35
- HOWL $1.10
- Average True Range (ATR)
- TRX 0.01
- HOWL 0.08
- MACD
- TRX 0.00
- HOWL 0.02
- Stochastic Oscillator
- TRX 78.00
- HOWL 82.40
About TRX TRX Gold Corporation
TRX Gold Corp is a mineral resource company. It is engaged in the acquisition of interests and the exploration of natural resource properties. Its mineral properties are located in the United Republic of Tanzania. The company's main area of interest has been in the exploration and development of gold properties. It is focused on the Buckreef Gold Project which comprises five prospects, namely Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.